Every 8-K that SANGAMO THERAPEUTICS INC (SGMO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SGMO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGMO filings page.
Sangamo Therapeutics, Inc. reported that its Audit Committee terminated Ernst & Young LLP as its independent registered public accounting firm on June 25, 2026, following the company’s previously announced voluntary Chapter 11 bankruptcy filing (Case No. 26-10989).
EY’s audit reports for the years ended December 31, 2024 and 2025 were unqualified but included an explanatory paragraph about Sangamo’s ability to continue as a going concern. The company states there were no disagreements or reportable events with EY through June 25, 2026 and has not yet engaged a new auditor.
Sangamo also noted that on June 24, 2026 its common stock began trading on the OTCID Basic Market under the symbol SGMOQ, while its Nasdaq Capital Market listing under SGMO remains in place during an ongoing appeal of a Nasdaq delisting determination.
Sangamo Therapeutics, Inc. filed Amendment No. 1 to a previously submitted current report to add two asset purchase agreements as exhibits. The amendment does not change any information previously disclosed in the original report covering Items 1.01, 1.03, 2.03 and 2.05.
The new exhibits are asset purchase agreements dated June 22, 2026, with counterparties including Eli Lilly and Company and Astellas Gene Therapies, Inc., along with certain Sangamo subsidiaries. The filing is administrative in nature and focused on completing the exhibit set.
Sangamo Therapeutics has filed for Chapter 11 bankruptcy protection in Delaware and will operate as a debtor-in-possession while it seeks to maximize value through asset sales. The company is pursuing two stalking horse transactions: a $50 million sale of its gene-editing and capsid platforms and related rights to Eli Lilly, and a sale of its Fabry disease program to Astellas for $25 million upfront plus up to $25 million in milestones, each subject to higher bids and court approval.
Sangamo has arranged a debtor-in-possession credit facility of up to $30 million, with an initial draw of up to $10.5 million pending court approval, secured by first priority liens on substantially all assets. The board also approved a major restructuring that will eliminate approximately 51 U.S. roles, about 40% of its workforce, leaving around 77 employees and generating expected severance and benefits costs of $3.0–$4.0 million plus about $0.5 million of paid-time-off payouts.
Sangamo Therapeutics reported a first quarter 2026 net loss of $31.0 million, or $0.08 per share, compared with a net loss of $30.6 million, or $0.14 per share, a year earlier. Revenue fell to $1.4 million from $6.4 million, mainly due to lower collaboration and license revenue.
GAAP operating expenses declined to $33.4 million, with non-GAAP operating expenses at $31.7 million, as the company reduced personnel and facilities costs while increasing spending on BLA readiness for its Fabry disease program. Cash and cash equivalents were $27.6 million as of March 31, 2026, which Sangamo estimates will fund operations into the third quarter of 2026.
The company advanced a rolling BLA for Fabry candidate ST-920 under an FDA Accelerated Approval pathway and continued early-stage neurology programs in chronic neuropathic pain and prion disease. Sangamo’s stock was suspended from Nasdaq for not meeting the minimum bid price and began trading on the OTCQB Venture Market on May 5, 2026, while the company appeals Nasdaq’s delisting determination.
Sangamo Therapeutics has been notified by Nasdaq that its common stock will be delisted for continued failure to meet the $1.00 per share minimum bid price requirement. Nasdaq plans to suspend trading on the Nasdaq Capital Market at the open on May 5, 2026.
The company plans to request a hearing before a Nasdaq Hearings Panel, which would stay the delisting determination but not the trading suspension. Sangamo has obtained approval for its shares to be quoted on the OTCQB Venture Market and expects OTCQB trading to begin on May 5, 2026 under the symbol SGMO.
Sangamo Therapeutics reported mixed 2025 results, combining major clinical progress with significant financial strain. The company highlighted positive topline data from its registrational STAAR study in Fabry disease and is advancing a rolling Biologics License Agreement submission for gene therapy candidate ST-920 under the FDA’s Accelerated Approval pathway.
Sangamo repositioned itself as a clinical-stage neurology company, with Fast Track Designation for chronic neuropathic pain candidate ST-503 and ongoing development of prion disease program ST-506. It also entered a third neurology capsid license agreement, this time with Eli Lilly, and has raised over $130 million since the start of 2025 through license fees, milestones and equity financing.
Financially, 2025 revenue fell to $39.6 million from $57.8 million in 2024, mainly due to lower Genentech collaboration revenue, partly offset by new payments from Lilly and Pfizer. Full-year net loss widened to $122.9 million. Cash and cash equivalents declined to $20.9 million at year-end, and total stockholders’ equity moved to a deficit of $14.3 million. Sangamo believes its cash, plus early 2026 financing inflows, will fund operations into the third quarter of 2026, and its 2026 operating expense guidance is explicitly dependent on securing additional funding.
Sangamo Therapeutics, Inc. entered into an underwritten public offering of 35,190,292 shares of common stock and pre-funded warrants for 17,787,033 shares, each paired with purchase warrants to buy a total of 52,977,325 shares. The combined offering prices are $0.4719 per common-share unit and $0.4619 per pre-funded warrant unit, with expected gross proceeds of approximately $25.0 million before fees, and closing expected on February 4, 2026, subject to customary conditions.
The pre-funded warrants are immediately exercisable at $0.01 per share with ownership caps up to 19.99%, while the purchase warrants become exercisable six months after issuance at $0.4719 per share for five and a half years, subject to a 4.99% ownership cap that can also be increased to 19.99%. In connection with the deal, Sangamo amended March 26, 2024 warrants held by the investor to reduce the exercise price on 23,809,523 shares from $1.00 to $0.4719 and extend their term to five and a half years from the offering’s closing.
Sangamo Therapeutics reported detailed Phase 1/2 STAAR data for its Fabry disease gene therapy isaralgagene civaparvovec (ST-920) and a clear U.S. regulatory path. The FDA agreed that this single Phase 1/2 study can serve as the primary basis for Accelerated Approval, using mean annualized eGFR slope at 52 weeks as the key endpoint.
The study treated 33 adults with a one-time infusion and showed a generally well-tolerated safety profile, with no deaths, no thrombotic microangiopathy or complement activation, and mostly mild or moderate adverse events. All 18 patients who entered on enzyme replacement therapy were able to stop ERT after dosing, while enzyme activity, kidney function slopes, cardiac measures, quality of life, gastrointestinal symptoms, and Fabry disease severity scores remained stable or improved over follow-up, supporting the ongoing rolling BLA submission.
Sangamo Therapeutics, Inc. reported a preliminary estimate that its cash and cash equivalents were approximately $20.9 million as of December 31, 2025. This figure is unaudited, subject to change, and may be adjusted when the audited financial statements for 2025 are completed.
The company also disclosed a leadership change in its finance team. On February 2, 2026, the employment of Prathyusha Duraibabu, the principal financial officer, terminated. Effective February 3, 2026, Nikunj Jain, Vice President, Finance and Corporate Controller and principal accounting officer, was appointed Interim Chief Financial Officer and will serve as the principal financial officer without additional compensation.
Sangamo Therapeutics (SGMO) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and is not incorporated by reference.
Sangamo Therapeutics (SGMO) reported a Nasdaq compliance update. The company received a 180-day extension—until April 27, 2026—to regain compliance with Nasdaq’s Minimum Bid Price Requirement of $1.00 per share. Compliance will be restored if the stock closes at or above $1.00 for at least 10 consecutive trading days before that date.
The extension has no immediate effect on SGMO’s Nasdaq Capital Market listing or SEC reporting. If compliance is not regained by April 27, 2026, Nasdaq may notify the company of a potential delisting, which SGMO could appeal under Nasdaq procedures.
Sangamo Therapeutics disclosed that its Chief Financial Officer, Prathyusha Duraibabu, resigned effective October 1, 2025 and will transition to part-time employment to continue as the company’s principal financial officer. The Board appointed Nikunj Jain, Vice President, Finance and Corporate Controller since September 2021, to serve as Sangamo’s principal accounting officer effective October 1, 2025. Mr. Jain’s employment agreement provides a $347,548 annual base salary and a target annual cash bonus equal to 30% of base salary; he remains eligible for annual equity awards and severance benefits under the company plans. Ms. Duraibabu’s amended agreement is expected to provide a $145,188 base salary and a $160,000 cash retention bonus payable January 31, 2026, subject to continued employment.
Sangamo Therapeutics reported that its Chief Financial Officer, Prathyusha Duraibabu, notified the company on September 9, 2025 that she will resign effective October 1, 2025 to join a privately-held artificial intelligence company. The filing states her departure is not due to any disagreement over the company’s operations, financial statements, internal controls, auditors, policies, or practices. For business continuity, Ms. Duraibabu will move to part-time employment on the Transition Date and will continue to serve as the company’s principal financial officer and principal accounting officer on an interim basis until a successor is appointed. The company acknowledged her contributions, including work on strategic collaborations and investment allocations as Sangamo focuses on becoming a neurology-focused genomic medicines company.
Sangamo Therapeutics (SGMO) presented updated registrational Phase 1/2 STAAR study data for isaralgagene civaparvovec (ST-920) for Fabry disease at ICIEM2025. As of the April 10, 2025 cutoff, 33 patients (age 18–67) were dosed with a median follow-up of 24 months and all 32 remaining patients had achieved at least 52 weeks of follow-up. The FDA agreed that STAAR data will serve as the primary basis for Accelerated Approval using the 52-week eGFR slope across patients as an intermediate clinical endpoint. Observed mean annualized eGFR slopes at 52 weeks were positive: 1.965 mL/min/1.73m2/year (95% CI: -0.153, 4.083) and RIRS estimate 2.020 (95% CI: -0.055, 4.095). Sangamo is preparing a BLA under Accelerated Approval with potential submission as early as Q1 2026, subject to securing additional funding.
Sangamo Therapeutics (SGMO) reported positive topline data from its registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for Fabry disease. In 32 treated adults, a single infusion produced a mean annualized eGFR slope of +1.965 mL/min/1.73 m²/year at 52 weeks, contrasting with published slopes of -2.2 to -0.4 mL/min for current standard therapies. Among 19 patients with 104-week follow-up, the slope remained positive at +1.747 mL/min, the FDA-endorsed intermediate endpoint for Accelerated Approval.
Secondary outcomes were uniformly favorable. All 18 patients initially on enzyme-replacement therapy discontinued ERT and remained off treatment, while plasma lyso-Gb3, cardiac parameters and α-Gal A activity stayed stable or improved for up to 4.5 years. Patient-reported outcomes showed statistically significant gains across multiple SF-36 domains and reductions in gastrointestinal symptoms, pain-medication use and anhidrosis.
Safety profile appeared benign: most adverse events were grade 1-2; no pre-conditioning, no safety-related discontinuations. The most common TEAEs were pyrexia (60.6%), COVID-19 (36.4%), headache (33.3%) and nasopharyngitis (33.3%).
The dataset supports SGMO’s plan to file a BLA under the Accelerated Approval pathway as early as Q1 2026. ST-920 already holds Orphan Drug, Fast Track and RMAT designations, plus EU and UK incentives. Full analyses will be presented at a future conference, and management is pursuing a commercialization partnership.